Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta‐analysis
- 24 October 2022
- journal article
- review article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 6644-6652
Abstract
Background: Tofacitinib, a potent JAK inhibitor, has gained increasing interest, in recent years, among dermatologists for the management of refractory alopecia areata. Despite a growing number of studies on its safety and efficacy, there is still a lack of clarity, especially in the pediatric population, in treatment considerations such as proper dosage, treatment duration, side‐effect profile, and therapeutic strategies to guide clinicians.Methods: Multiple databases were systematically searched. Following the PRISMA diagram, of a pool of 601 papers, seven met a checklist of inclusion criteria. These were observational studies including a total of 59 patients from four to 19 years of age.Results: In the evaluated studies, tofacitinib was administered either orally at a 2.5 to 15 mg daily (mostly 5 mg twice a day) dosage for 2 to 38 months or in the form of a 2% topical solution for 3–17 months. Metanalysis showed that 49% (95% CI: 29%–69%, I2 = 59.94%) of patients experienced a reversal of alopecia after a minimum of 3 to 9 months of therapy. Fifty‐five percent (95% CI: 23%–86%, I2 = 75.07%) and 41% (95% CI: 23%–59%, I2 = 0.00%) showed Good/complete and partial response rates, respectively. Oral administration was significantly more efficacious than topical application (73% vs 23%, p‐Value = 0.04). Few side effects such as diarrhea and mild liver transaminases abnormalities were noted in several patients.Conclusion: Results of this review suggest that tofacitinib at 2.5–15 mg daily (especially 5 mg twice daily) oral formulation or 2% topical solution can be regarded as a viable alternative or adjunct to the conventional treatment options for moderate to severe forms of alopecia areata in children owing to its acceptable efficacy and side‐effect profile. However, uncertainties continue to exist around treatment strategies including initial and maintenance dosages, route of administration, dose adjustments, the timing of tapering or discontinuation, and associated treatment modalities.Keywords
This publication has 30 references indexed in Scilit:
- Lifetime Incidence Risk of Alopecia Areata Estimated at 2.1% by Rochester Epidemiology Project, 1990–2009Journal of Investigative Dermatology, 2014
- The Role of Hair Follicle Immune Privilege Collapse in Alopecia Areata: Status and PerspectivesJournal of Investigative Dermatology Symposium Proceedings, 2013
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunityNature, 2010
- Interferon-γ-deficient mice are resistant to the development of alopecia areataBritish Journal of Dermatology, 2006
- Reduced Expression of Interleukin-2 Decreases the Frequency of Alopecia Areata Onset in C3H/HeJ MiceJournal of Investigative Dermatology, 2005
- Alopecia Areata Induced in C3H/HeJ Mice by Interferon-Gamma: Evidence for Loss of Immune PrivilegeJournal of Investigative Dermatology, 2005
- Alopecia areata investigational assessment guidelines–Part IIJournal of the American Academy of Dermatology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- The human hair follicle immune system: cellular composition and immune privilegeBritish Journal of Dermatology, 2000
- Interleukin-15 Induces the Expression of mRNAs of Cytolytic Mediators and Augments Cytotoxic Activities in Primary Murine LymphocytesCellular Immunology, 1996